Abandoning clinical trial safeguards won’t boost local industry

Access status:

Open Access

Field	Value	Language
dc.contributor.author	Komesaroff, P
dc.contributor.author	Thomson, C
dc.contributor.author	Kerridge, I
dc.date.accessioned	2014-08-09
dc.date.available	2014-08-09
dc.date.issued	2013-10-07
dc.identifier.citation	Komesaroff P, Thomson C, Kerridge I, (2013) Abandoning clinical trial safeguards won’t boost local industry, The Conversation	en
dc.identifier.uri	http://hdl.handle.net/2123/11600
dc.description.abstract	Testing new drugs in clinical trials is a billion-dollar industry in Australia, with most of the money coming from international pharmaceutical companies. But as investment grows in India, China, and other emerging competitors, some people argue we need to make Australia more attractive to such investment. One of their solutions is to water down the ethics approval process.	en
dc.language.iso	en_AU	en
dc.publisher	The Conversation	en
dc.rights	Other
dc.title	Abandoning clinical trial safeguards won’t boost local industry	en
dc.type	Article	en
usyd.faculty	Faculty of Medicine and Health, Sydney Health Ethics